Literature DB >> 26227347

Thirty-Day Readmissions After Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis in New York State.

Edward L Hannan1, Zaza Samadashvili2, Desmond Jordan2, Thoralf M Sundt2, Nicholas J Stamato2, Stephen J Lahey2, Jeffrey P Gold2, Andrew Wechsler2, Mohammed H Ashraf2, Carlos Ruiz2, Sean Wilson2, Craig R Smith2.   

Abstract

BACKGROUND: Several studies have compared short-term and medium-term mortality rates for patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR), but no studies have compared short-term readmission rates for the 2 procedures. METHODS AND
RESULTS: New York's Cardiac Surgery Reporting System was used to propensity match 617 TAVI and 1981 SAVR patients using numerous patient risk factors contained in the registry. The 389 propensity-matched pairs were then used to analyze differences in readmission rates between the 2 groups. TAVI and SAVR readmission rates were also compared for patients with a history of congestive heart failure and for patients aged ≥80. Also, reasons for readmission for TAVI and SAVR patients were examined and compared. Readmission rates were not statistically different for all propensity-matched TAVI and SAVR patients (respective rates, 18.8% and 19.3%; P=0.86). After further adjustment using a logistic regression model, there was still no significant difference (adjusted odds ratio, 0.97; 95% confidence interval [0.68-1.39]). For patients aged ≥80, the 30-day readmission rates were 19.9% and 22.0% (P=0.59), and when further adjusted using the logistic regression model, adjusted odds ratio=0.89 (0.55-1.45). For patients with a history of congestive heart failure, the respective rates were 22.8% and 20.4% (P=0.56), and with further adjustment, adjusted odds ratio became 1.15 (0.72-1.82).
CONCLUSIONS: There are no statistically significant differences between TAVI and SAVR patients in short-term readmission rates.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve stenosis; heart failure; patient readmission; risk factors; transcatheter aortic valve replacement

Mesh:

Year:  2015        PMID: 26227347     DOI: 10.1161/CIRCINTERVENTIONS.115.002744

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  11 in total

1.  Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement.

Authors:  Sahil Khera; Dhaval Kolte; Tanush Gupta; Andrew Goldsweig; Poonam Velagapudi; Ankur Kalra; Gilbert H L Tang; Wilbert S Aronow; Gregg C Fonarow; Deepak L Bhatt; Herbert D Aronow; Neal S Kleiman; Michael Reardon; Paul C Gordon; Barry Sharaf; J Dawn Abbott
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 2.  Causes and predictors of readmission after transcatheter aortic valve implantation : A meta-analysis and systematic review.

Authors:  Yi-Ming Li; Fu-Yang Mei; Yi-Jun Yao; Jia-Yu Tsauo; Yong Peng; Mao Chen
Journal:  Herz       Date:  2019-12-05       Impact factor: 1.443

3.  Real-life outcomes and readmissions after a TAVI procedure in a Glasgow population.

Authors:  Joanna Osmanska; David Murdoch
Journal:  Br J Cardiol       Date:  2021-09-01

4.  Trends in Readmission and Costs After Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With Renal Dysfunction.

Authors:  Yas Sanaiha; Aditya Mantha; Boback Ziaeian; Yen-Yi Juo; Richard J Shemin; Peyman Benharash
Journal:  Am J Cardiol       Date:  2019-02-08       Impact factor: 2.778

5.  Readmissions after transcatheter aortic valve implantation. What are they doing right? How can we do better?

Authors:  Devraj Sukul; David S Bach
Journal:  Eur Heart J       Date:  2017-07-21       Impact factor: 29.983

6.  Readmissions and mortality in delirious versus non-delirious octogenarian patients after aortic valve therapy: a prospective cohort study.

Authors:  Leslie S P Eide; Anette H Ranhoff; Bengt Fridlund; Rune Haaverstad; Karl Ove Hufthammer; Karel K J Kuiper; Jan Erik Nordrehaug; Tone M Norekvål
Journal:  BMJ Open       Date:  2016-10-05       Impact factor: 2.692

7.  Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry.

Authors:  Kazuki Mizutani; Masahiko Hara; Shinichi Iwata; Takashi Murakami; Toshihiko Shibata; Minoru Yoshiyama; Toru Naganuma; Futoshi Yamanaka; Akihiro Higashimori; Norio Tada; Kensuke Takagi; Motoharu Araki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

8.  Determining the impact of 24/7 phone support on hospital readmissions after aortic valve replacement surgery (the AVRre study): study protocol for a randomised controlled trial.

Authors:  Irene Lie; Stein Ove Danielsen; Theis Tønnessen; Svein Solheim; Marit Leegaard; Leiv Sandvik; Torbjørn Wisløff; Jonny Vangen; Tor Henning Røsstad; Philip Moons
Journal:  Trials       Date:  2017-05-30       Impact factor: 2.279

9.  Profiling Hospital Performance on the Basis of Readmission After Transcatheter Aortic Valve Replacement in Ontario, Canada.

Authors:  Gabby Elbaz-Greener; Feng Qiu; John G Webb; Kayley A Henning; Dennis T Ko; Andrew Czarnecki; Idan Roifman; Peter C Austin; Harindra C Wijeysundera
Journal:  J Am Heart Assoc       Date:  2019-06-05       Impact factor: 5.501

10.  Center Variability in Medicare Claims-Based Publicly Reported Transcatheter Aortic Valve Replacement Outcome Measures.

Authors:  Michael P Thompson; Hechuan Hou; Alexander A Brescia; Francis D Pagani; Devraj Sukul; Jeffrey S McCullough; Donald S Likosky
Journal:  J Am Heart Assoc       Date:  2021-10-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.